Q&A: Analyzing Blood, Not the Tumor: A Novel Test for Personalized Cancer Immunotherapy15 Oct 2023 17:19
How does the EpiSwitch CiRT address these challenges?
To my knowledge, the predictive value achieved by CiRT centers on capturing the host's immune profile as it is associated with the clinical benefit of immune checkpoint inhibitors (ICIs) from circulating immunosurveillance white blood cells. The EpiSwitch CiRT is a simple blood test that identifies an individual patient’s likely response to ICI therapy with 85 percent accuracy, thereby aiding clinicians like me in making more informed, personalized treatment decisions without an invasive biopsy. The test can be administered before, during, or after treatment with ICIs or standard of care, such as chemoradiation. This unique diagnostic approach piqued my interest when I first saw the CIRT performance data presented in Paris at the annual European Society of Medical Oncology (ESMO) meeting last September and had continued discussions with the clinical scientists of the company. After ESMO, I began using the CiRT blood test to help fill knowledge gaps in current immunotherapy placement schemas.
Because immunotherapy exploits the innate capacity of the immune system's ability to detect and destroy malignancies, having assays such as CiRT alongside standard diagnostic modalities provides me with a more comprehensive view of and for my patients.
The application of CiRT is extensive, having demonstrated best-in-class performance across five anti-PD-1/L1 ICIs and more than 14 broad oncological indications, including melanoma, lymphoma, lung, prostate, and breast cancer.
https://www.genomeweb.com/liquid-biopsy/qa-analyzing-blood-not-tumor-novel-test-personalized-cancer-immunotherapy?utm_source=social&utm_medium=article%20&utm_campaign=gw-long-form
Sign In
Follow the stocks
